经颈动脉血运重建与颈动脉支架术治疗无症状颈动脉狭窄的比较
本研究基于TriNetX数据库比较无症状颈动脉狭窄患者接受经颈动脉血运重建(TCAR)与颈动脉支架术(CAS)的缺血性卒中结局。倾向性评分匹配后每组2207例,TCAR组卒中风险与CAS组无显著差异(HR 0.68,95%CI 0.44-1.06),绝对风险差随时间扩大但均未达统计学显著性。结论认为TCAR未显著降低卒中风险,观察到的非显著趋势更可能反映残余混杂而非手术获益。
要点
- 匹配后TCAR与CAS的4年缺血性卒中风险无显著差异(HR 0.68,95%CI 0.44-1.06)。
- 绝对风险差从6个月0.35%扩大至4年1.55%,但均未达统计学显著性。
- 非显著趋势随时间扩大提示残余混杂,而非TCAR的真实获益。
核心结论
- 对于无症状颈动脉狭窄,TCAR与CAS相比未显著降低缺血性卒中风险。
- 观察到的TCAR较低卒中风险趋势不显著,且绝对风险差随时间扩大,提示残余混杂而非手术获益。
研究设计与样本
- 基于2016至2024年TriNetX多中心电子健康记录联邦数据库的回顾性队列研究。
- 纳入成人无症状颈动脉狭窄接受TCAR或CAS的患者,经倾向性评分匹配 demographics、实验室值、危险因素、合并症和药物。
- 共识别7303例患者,匹配后每组各2207例。
- 主要结局为4年内缺血性卒中。
主要发现
- TCAR与CAS的卒中风险无显著差异(风险比0.68,95%CI 0.44-1.06)。
- TCAR组绝对风险差在整个随访期数值上较低但无统计学显著性:6个月为0.35%(0.61% vs 0.96%,P=0.18)。
- 4年绝对风险差为1.55%(3.26% vs 4.81%,P=0.086)。
临床怎么用
- 在无症状颈动脉狭窄患者中,选择TCAR或CAS时不应预期TCAR能显著降低卒中风险。
- 需结合个体化评估和长期随访数据综合决策,不能仅凭非显著趋势倾向TCAR。
局限性
- 观察性设计可能受残余混杂影响,非显著趋势随时间扩大提示混杂可能。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The CREST-2 trial (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial) demonstrated superiority of carotid artery stenting (CAS) over intensive medical management for asymptomatic carotid stenosis, but it did not evaluate transcarotid artery revascularization (TCAR). Herein, we compared ischemic stroke outcomes between TCAR and CAS among patients with asymptomatic carotid stenosis in contemporary real-world practice. METHODS: We identified adults with asymptomatic carotid stenosis undergoing TCAR versus CAS using the 2016 to 2024 TriNetX database, which is a multicenter federated database of electronic health records. Propensity score matching was performed for demographics, laboratory values, risk factors, comorbidities, and medications. The primary outcome was ischemic stroke within 4 years. RESULTS: Among 7303 identified patients, 2207 patients remained in each group after matching. TCAR did not demonstrate a significantly different stroke risk compared with CAS (hazard ratio, 0.68 [95% CI, 0.44-1.06]). The absolute risk difference was numerically but nonsignificantly lower for patients with TCAR throughout the follow-up period, progressively widening over time: 0.35% at 6 months (0.61% versus 0.96%; P=0.18) to 1.55% at 4 years (3.26% versus 4.81%; P=0.086). CONCLUSIONS: TCAR did not significantly lower stroke risk compared with CAS for asymptomatic carotid stenosis. Although nonsignificant trends towards lower stroke risk were observed for TCAR, the widening of absolute risk differences over time suggests residual confounding rather than potential procedural benefit.
引用
- Chen H, Lakhani DA, Colasurdo M, et al. Transcarotid Artery Revascularization Versus Carotid Artery Stenting for Asymptomatic Carotid Stenosis. Stroke. 2026. PMID: 42734077. doi:10.1161/STROKEAHA.126.055324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。